Patents by Inventor Klaus Giese

Klaus Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERFERING RNA MOLECULES
    Publication number: 20160130587
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: December 22, 2015
    Publication date: May 12, 2016
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Interfering RNA molecules
    Patent number: 9222092
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: December 29, 2015
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • USE OF VEGFR1 AS A BIOMARKER
    Publication number: 20150368650
    Abstract: The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.
    Type: Application
    Filed: August 28, 2015
    Publication date: December 24, 2015
    Inventors: KLAUS GIESE, JOERG KAUFMANN
  • Use of VEGFR1 as a biomarker
    Patent number: 9133515
    Abstract: The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: September 15, 2015
    Assignee: SILENCE THERAPEUTICS GMBH
    Inventors: Klaus Giese, Joerg Kaufmann
  • INTERFERING RNA MOLECULES
    Publication number: 20150105545
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Inventors: KLAUS GIESE, JÖRG KAUFMANN, ANKE KLIPPEL-GIESE
  • Interfering RNA molecules
    Patent number: 8933215
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: January 13, 2015
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • USE OF VEGFR1 AS A BIOMARKER
    Publication number: 20140179755
    Abstract: The present invention is related to the use of VEGFR1 or of a nucleic acid coding for VEGFR1 as a biomarker in a method for the treatment of a subject, wherein the method for the treatment comprises administering to the subject a PKN3 inhibitor.
    Type: Application
    Filed: May 15, 2013
    Publication date: June 26, 2014
    Inventors: KLAUS GIESE, JOERG KAUFMANN
  • Therapeutic uses of inhibitors of RTP801
    Patent number: 8642571
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: February 4, 2014
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • THERAPEUTIC USES OF INHIBITORS OF RTP801
    Publication number: 20130095117
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Application
    Filed: August 31, 2012
    Publication date: April 18, 2013
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Interfering RNA molecules
    Patent number: 8324370
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: December 4, 2012
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Therapeutic uses of inhibitors of RTP801
    Patent number: 8309532
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: November 13, 2012
    Assignee: Quark Pharmaceuticals, Inc.
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Methods of treating eye diseases in diabetic patients
    Patent number: 8168607
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: May 1, 2012
    Assignees: Quark Pharmaceuticals Inc., Silence Therapeutics AG
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Interfering RNA Molecules
    Publication number: 20110118456
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 19, 2011
    Applicant: SILENCE THERAPEUTICS AG
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Therapeutic uses of inhibitors of RTP801
    Publication number: 20110117102
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Application
    Filed: June 17, 2010
    Publication date: May 19, 2011
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Interfering RNA molecules
    Patent number: 7893245
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: February 22, 2011
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese
  • Methods of treating eye diseases in diabetic patients
    Publication number: 20110028532
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Application
    Filed: June 7, 2010
    Publication date: February 3, 2011
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • Metastatic breast and colon cancer regulated genes
    Patent number: 7795407
    Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.
    Type: Grant
    Filed: January 24, 2007
    Date of Patent: September 14, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Hong Xin, Klaus Giese
  • Therapeutic uses of inhibitors of RTP801
    Patent number: 7741299
    Abstract: The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: June 22, 2010
    Assignees: Quark Pharmaceuticals, Inc., Silence Therapeutics AG
    Inventors: Elena Feinstein, Jorg Kaufmann, Klaus Giese
  • INTERFERING RNA MOLECULES
    Publication number: 20090186845
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Application
    Filed: August 28, 2008
    Publication date: July 23, 2009
    Applicant: SILENCE THERAPEUTICS AG
    Inventors: KLAUS GIESE, Jorg Kaufmann, Anke Klippel-Giese
  • Interfering RNA molecules
    Patent number: 7452987
    Abstract: The present invention is related to a ribonucleic acid comprising a double stranded structure whereby the double-stranded structure comprises a first strand and a second strand, whereby the first strand comprises a first stretch of contiguous nucleotides and whereby said first stretch is at least partially complementary to a target nucleic acid, and the second strand comprises a second stretch of contiguous nucleotides whereby said second stretch is at least partially identical to a target nucleic acid, and whereby the double stranded structure is blunt ended.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: November 18, 2008
    Assignee: Silence Therapeutics Aktiengesellschaft (AG)
    Inventors: Klaus Giese, Jörg Kaufmann, Anke Klippel-Giese